Skip main navigation

Main contents starts here

Co-development and Out Licensing

To provide excellent drugs to patients and medical service providers as early as possible, we promote cooperative development and sales and out-licensing of our compounds through alliances based on the targeted disease or compound if it is more effective to let a partner with required know-how handle the matter or to conduct joint development.

Licensee Product Name or Development Code Drug Class Indication(s) Territory Time
Tobira

TAK-220/TAK-652

CCR5 antagonist

HIV Infection

Worldwide

Aug.07

Peninsula Pharmaceuticals

TAK-599

Cephalosporin

Infection

Worldwide except Japan

Sep.03


Skip side navigation

Skip sub navigation

Page Top